SCHEMBL3757194

SCHEMBL3757194

CCCCCCCCCCCCOc1ccc(C2SCCCS2)cc1OCCCCCCCCCCCC

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.45
PDE4A P27815 3/20 0.40
PDE4B Q07343 1/20 0.40
PDE4C Q08493 1/20 0.40
PDE4D Q08499 1/20 0.40
SMPD1 P17405 5/20 0.38
MAOA P21397 1/20 0.36
MAOB P27338 1/20 0.36
CHUK O15111 1/20 0.36
DAPK3 O43293 1/20 0.36
JAK2 O60674 1/20 0.36
ROCK2 O75116 1/20 0.36
PRKCG P05129 1/20 0.36
CDK1 P06493 1/20 0.36
PIM1 P11309 1/20 0.36
RPS6KB1 P23443 1/20 0.36
CDK2 P24941 1/20 0.36
AKT1 P31749 1/20 0.36
AKT2 P31751 1/20 0.36
MAPKAPK2 P49137 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8059997 0.94 TSHR (0.47) TSHRPDE4APDE4BPDE4CPDE4D
SCHEMBL8058003 0.93 TSHR (0.51) TSHRPDE4APDE4BPDE4CPDE4D
SCHEMBL8057965 0.88 TSHR (0.53) TSHRPDE4APDE4BPDE4CPDE4D
SCHEMBL8064807 0.88 TSHR (0.53) TSHRPDE4APDE4BPDE4CPDE4D
SCHEMBL8059968 0.88 TSHR (0.47) TSHRPDE4APDE4BPDE4CPDE4D
SCHEMBL9778850 0.77 TSHR (0.57) TSHRPDE4APDE4BPDE4CPDE4D
SCHEMBL9778782 0.77 TSHR (0.57) TSHRPDE4AALDH1A1HPGDGAA
SCHEMBL9778629 0.77 SIGMAR1 (0.41) TSHRALDH1A1HPGDMAPTPPARG
SCHEMBL12883744 0.76 MAOA (0.55) TSHRMAOAMAOBALDH1A1MAPT
SCHEMBL9778863 0.74 KDM4E (0.47) TSHRPDE4APDE4BPDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7842830-B2 Transition-metal charge-transport materials, methods of fabrication thereof, and methods of use thereof GEORGIA TECH RESEARCH CORPORATION (US) 2010-11-30 US disclosed
US-7842830-B2 Transition-metal charge-transport materials, methods of fabrication thereof, and methods of use thereof GEORGIA TECH RESEARCH CORPORATION (US) 2010-11-30 US disclosed
US-20080121870-A1 Transition-Metal Charge Transport Materials, Methods Of Fabrication Thereof, And Methods Of Use Thereof GEORGIA TECH RESEACH CORPORATION 2008-05-29 US disclosed
US-20080121870-A1 Transition-Metal Charge Transport Materials, Methods Of Fabrication Thereof, And Methods Of Use Thereof GEORGIA TECH RESEACH CORPORATION 2008-05-29 US disclosed
WO-2005123754-A2 TRANSITION-METAL CHARGE-TRANSPORT MATERIALS, METHODS OF FABRICATION THEREOF, AND METHODS OF USE THEREOF GEORGIA TECH RESEARCH CORPORATION (US) 2005-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080121870-A1 Transition-Metal Charge Transport Materials, Methods Of Fabrication Thereof, And Methods Of Use Thereof SLC39A3, SLC6A6, SLC6A9 TSHR 4527/4885PDE4A 4483/4885PDE4B 4487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.